Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.

Van den Wyngaert, Tim;Delforge, M;Doyen, Chantal;Duck, L;Wildiers, H;et.al.
(2013) Supportive Care in Cancer — Vol. 21, n° 12, p. 3483-3490 (2013)

Files

VandenWyngaertTDoyenC-SupportCareCancer2013.pdf
  • Restricted Access
  • Adobe PDF
  • 347.13 KB
Request a copy

Details

Authors
  • Van den Wyngaert, TimAntwerp University Hospital
    Author
  • Delforge, MUniversity Hospitals Leuven
    Author
  • Doyen, ChantalUCLouvain
    Author
  • Duck, LClinique St Pierre Ottignies
    Author
  • Wildiers, H
    Author
Show more
Abstract
To study the treatment patterns, effectiveness and safety of zoledronic acid (ZOL) beyond 2 years of therapy, given the paucity of data on long-term treatment in daily clinical practice.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Van den Wyngaert, T., Delforge, M., Doyen, C., Duck, L., Wouters, K., Delabaye, I., Wouters, C., & Wildiers, H. (2013). Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors. Supportive Care in Cancer, 21(12), 3483-3490. https://doi.org/10.1007/s00520-013-1934-0 (Original work published 2013)